Industry

Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022

BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC). The data show that poziotinib is highly active in G778 mutations in both treatment … [Read more…]

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

– Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs” at the 2022 European … [Read more…]

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Patients Treated With Both Doses of CTP-543 MILAN–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the … [Read more…]

DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer

Extended follow-up data from phase 1/2 trial of DS-7300 in patients with metastatic lung, prostate or esophageal cancer to be featured in Proffered Paper session at ESMO TOKYO, BASKING RIDGE, N.J. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (SCRI) announced that extended follow-up data from a phase 1/2 trial of … [Read more…]

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

— WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function — — WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and penetration further augmented by monoclonal antibodies (mAbs) — — Data support the clinical development of WU-NK-101 for solid tumor indications — ST. LOUIS & … [Read more…]

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

– Both single-agent XL092 and XL092 in combination with atezolizumab demonstrated encouraging efficacy and safety in a heavily pretreated patient population – – XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile – – Based on … [Read more…]

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis New analysis to be presented at the 2022 European Academy of Dermatology and Venereology Congress as part of 26 company-sponsored scientific presentations, demonstrating … [Read more…]

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022 RAHWAY, N.J. & NUTLEY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 … [Read more…]

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trial Additional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combination CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on … [Read more…]

  U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

  Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years Pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy of once-daily Sotyktu over placebo and twice-daily Otezla® (apremilast) … [Read more…]